Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Hypothesis Testing01:11

Types of Hypothesis Testing

29.5K
There are three types of hypothesis tests: right-tailed, left-tailed, and two-tailed.
When the null and alternative hypotheses are stated, it is observed that the null hypothesis is a neutral statement against which the alternative hypothesis is tested. The alternative hypothesis is a claim that instead has a certain direction. If the null hypothesis claims that p = 0.5, the alternative hypothesis would be an opposing statement to this and can be put either p > 0.5, p < 0.5, or p...
29.5K
Testing a Claim about Population Proportion01:24

Testing a Claim about Population Proportion

4.1K
A complete procedure for testing a claim about a population proportion is provided here.
There are two methods of testing a claim about a population proportion: (1) Using the sample proportion from the data where a binomial distribution is approximated to the normal distribution and (2) Using the binomial probabilities calculated from the data.
The first method uses normal distribution as an approximation to the binomial distribution. The requirements are as follows: sample size is large...
4.1K
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

701
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
701
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

520
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
520
Null and Alternative Hypotheses01:16

Null and Alternative Hypotheses

13.3K
The actual hypothesis testing begins by considering two hypotheses. They are termed  the null hypothesis and the alternative hypothesis. These hypotheses contain opposing viewpoints.
The null hypothesis, denoted by H0 is a statement of no difference between the variables—they are not related. This can often be considered the status quo. As  a result if you cannot accept the null, it requires some action.
The alternative hypothesis, denoted by H1 or Ha, is a claim about the...
13.3K
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

207
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
207

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A prematurely terminated phase 2, randomised trial to evaluate immunogenicity and reactogenicity of a single versus two-dose primary vaccination regimen of the mRNA vaccine BNT162b2 in previously SARS-CoV-2 infected children 5-11 years old (CoVacc trial).

Vaccine·2026
Same author

Impact of Information Leakage in Platform Trials With Survival Endpoints on Type I Error Control.

Pharmaceutical statistics·2026
Same author

Comparison of three different hpv self-sampling tools - a subanalysis of the prospective, randomized hannover self-collection study.

Archives of gynecology and obstetrics·2026
Same author

DIGIT-HF: Results From the Win Ratio Analyses.

Circulation. Heart failure·2026
Same author

On the Inclusion of Non-Concurrent Controls in Platform Trials With an Interim Analysis.

Statistics in medicine·2026
Same author

Choriocapillaris Flow-Enriched Prediction of Retinal Sensitivity Using OCT-Derived Biomarkers in Intermediate Age-Related Macular Degeneration.

Journal of clinical medicine·2026
Same journal

A Mixture of Distributed Lag Non-Linear Models to Account for Spatially Heterogeneous Exposure-Lag-Response Associations.

Statistics in medicine·2026
Same journal

Practical Considerations for Gaussian Process Modeling for Causal Inference in Quasi-Experimental Studies With Panel Data.

Statistics in medicine·2026
Same journal

Covariate Adjustment for Wilcoxon Two Sample Statistic and Test.

Statistics in medicine·2026
Same journal

Beyond Fixed Thresholds: Optimizing Summaries of Wearable Device Data via Piecewise Linearization of Quantile Functions.

Statistics in medicine·2026
Same journal

A Causal Framework for Evaluating the Total Effect of Strategies Aiming to Expand Screening and to Improve Outcomes.

Statistics in medicine·2026
Same journal

Causal Effects on Nonterminal Event Time With Application to Antibiotic Usage and Future Resistance.

Statistics in medicine·2026
See all related articles

Related Experiment Video

Updated: Mar 25, 2026

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.7K

Fallback tests for co-primary endpoints.

Robin Ristl1, Florian Frommlet1, Armin Koch2

  • 1Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Spitalgasse 23, 1090 Vienna, Austria.

Statistics in Medicine
|February 27, 2016
PubMed
Summary
This summary is machine-generated.

Fallback tests improve clinical trial analysis when using co-primary endpoints. These methods allow for continued inference even if not all endpoints meet statistical significance, enhancing treatment efficacy evaluation.

Keywords:
Rüger testdiagonally trimmed Simes testmultiple endpointsmultiple testingsmall populations

More Related Videos

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

9.3K
Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

1.0K

Related Experiment Videos

Last Updated: Mar 25, 2026

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.7K
E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

9.3K
Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

1.0K

Area of Science:

  • Biostatistics
  • Clinical Trial Design
  • Statistical Inference

Background:

  • Traditional analysis of co-primary endpoints requires significance on all tests, often leading to conservative results and inability to infer partial treatment effects.
  • This strict approach can limit the interpretation of clinical trial outcomes, especially when only a subset of endpoints demonstrates efficacy.

Purpose of the Study:

  • To introduce and evaluate fallback tests as an improvement over classical methods for co-primary endpoints in clinical trials.
  • To develop fallback procedures that control the family-wise type I error rate (FWER) in the strong sense, allowing for continued inference even if not all endpoints are significant.

Main Methods:

  • Investigated fallback tests as uniform improvements to classical tests for co-primary endpoints.
  • Proposed and analyzed fallback tests for two and three co-primary endpoints, assuming multivariate normal test statistics with an arbitrary correlation matrix.
  • Conducted a simulation study to assess the power of the proposed fallback procedures.

Main Results:

  • The proposed fallback tests control the family-wise type I error rate (FWER) in the strong sense.
  • These procedures offer increased power compared to classical methods, particularly when only a subset of co-primary endpoints is significant.
  • Simulations demonstrated the practical utility and statistical validity of the fallback approach.

Conclusions:

  • Fallback tests provide a more flexible and powerful approach for analyzing co-primary endpoints in clinical trials.
  • They enable continued inference and interpretation of results even when the primary trial objective (all endpoints significant) is not fully met.
  • The application of fallback procedures in rare disease and diagnostic trials highlights their real-world applicability.